Browse > Article

CLINICAL STUDY OF BISPHOSPHONATE-INDUCED OSTEONECROSIS OF MANDIBULAR AND MAXILLARY BONE  

Joeng, Hye-Rin (Department of Dentistry, School of Medicine, Ajou University)
Kim, Tae-Wan (Department of Dentistry, School of Medicine, Ajou University)
Lee, Jeong-Keun (Department of Dentistry, School of Medicine, Ajou University)
Song, Seung-Il (Department of Dentistry, School of Medicine, Ajou University)
Publication Information
Journal of the Korean Association of Oral and Maxillofacial Surgeons / v.35, no.5, 2009 , pp. 353-360 More about this Journal
Abstract
Bisphosphonates are compounds widely used in the treatment of various metabolic and malignant bone disease. Recently, an association between bisphosphonate use and a rare dental condition termed 'osteonecrosis of the jaw(ONJ)' has been reported. Bisphosphonate-related osteonecrosis of the jaw(BRONJ) is rare, but serious, side effect of bisphosphonate therapy in affected patients. It is characterized by poor wound healing and spontaneous intra-oral soft tissue break down, which lead to exposure of necrotic maxillary and mandibular bone. We reviewed 11 patients of BRONJ visited Ajou University Hospital Dental clinic from May 2007 to November 2008. The management of the patients included cessation of bisphosphonate therapy and various surgical restorative procedures and conservative care there after. Aggressive debridement is contraindicated. A new complication of bisphosphonate therapy administration, osteonecrosis of jaws, seems to be developing. The improved results after cessation of the medication should make clinicians reconsider the merits of the rampant use of bisphosphonates, while further investigation is needed to completely elucidate this complication.
Keywords
BRONJ (Bisphosphonate-related osteonecrosis of the jaw); Osteonecrosis; Osteoporosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Khosla S, Burr D, Cauley J. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91   DOI   PUBMED   ScienceOn
2 Wilkinson G, Kuo YF, Freeman KJ. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016-24   DOI   PUBMED   ScienceOn
3 Drexler HC, Risaw W, Konerding MA.: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;20:4319-23   PUBMED
4 Schulze D, Blessmann M, Pohlenz P. Diagnostic criteria for the detection of mandibular osteomyelitis using cone-beam computed tomography. Dentomaxillofac Radiol 2006;35:232-5   DOI   PUBMED   ScienceOn
5 Wutzl A, Eisenmenger G, Hoffmann M. Osteonecrosis of the jaws and bisphosphonate treatmentin cancer patients. Wien Klin Wochenschr 2006;118:473-8   DOI   PUBMED   ScienceOn
6 Rizzoli R, Pierre D, Burlet NS. Review: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42: 841-7   DOI   PUBMED   ScienceOn
7 Chhoeu AH, Siegel D. Landesberg R, Althoff M. A case series of hyperbaric oxygen treatment for non-radiation induced osteonecrosis of the jaw. J Oral MaxillofacSurg. 2006;64(Sup):80-1   DOI   ScienceOn
8 Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34(Suppl 4):S17-S23   DOI   PUBMED   ScienceOn
9 Migliorati CA, Casiglia J, Epstein J. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J AM Dent Assoc 2005;136:1658-68   PUBMED
10 Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-23   DOI   PUBMED   ScienceOn
11 Yarom N, Yahalom R, Shoshani Y. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-70   DOI   PUBMED   ScienceOn
12 Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphophonates: current issues. J Support Oncol 2007;5:475-82   PUBMED
13 Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone 2006;38:613-6   DOI   PUBMED   ScienceOn
14 Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonate. Med 2005;353:99-102   DOI   PUBMED
15 Ruggiero SL, Mehrotra B, Rosenberg TJ. Osteonecrosis of the jaws associated with the use of bisphosphonates : a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34   DOI   PUBMED   ScienceOn
16 Phal PM, Myall RW, Assael LA. Imaging findings of bisphoshonate-associated osteonecrosis of the jaws. Am J Neuroradiol 2007;28:1139-45   DOI   PUBMED   ScienceOn
17 Reid IR. Bolland MJ. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20   DOI   PUBMED   ScienceOn
18 Kwon YD, Yoon BW, Walter C. Bisphosphonate, is it an emerging risk factor in oral surgery? J Kor Maxillofac Plastic Recon Surg 2007;29:456-62   과학기술학회마을
19 Marx RE. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. 1st ed. Chicago: Quintessence Publishing, 2007
20 Rogers MJ, Gordon S, Benford HL. Cellular and molecular mechanism of action of bisphosphonates. Cancer 2000: 88(Suppl): 2961-78   PUBMED
21 Mavrokokki A, Cheng A, Stein B. Nature and frequency of bisphosphonate -associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23   DOI   PUBMED   ScienceOn
22 Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76   DOI   PUBMED   ScienceOn
23 Guerrero ME, Jacobs R, Loubele M. State-of-the-art on cone beam CT imaging for preoperative planning of implant placement. Clin Oral Investig 2006;10:1-7   DOI   PUBMED   ScienceOn
24 Marx RE, Sawatari Y, Fortin M. BroumanV.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567-75   DOI   PUBMED   ScienceOn
25 Marx RE. Pamidronate (AREDIA) and zoledronate(ZOMETA) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115 -8   DOI   PUBMED   ScienceOn
26 Lam DK, Sandor GK, Holmes HI. A review of bisphos phonate - associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73: 417-22   PUBMED
27 Berenson JR, Hillner BE, Kyle RA, American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Clin Oncol 2002;20:3719-36   DOI   PUBMED   ScienceOn
28 Owens G, Jackson R, Lewiecki EM. An integrated approach:bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007;13 Suppl 11): S290-S308   PUBMED
29 Woo SB, Hellstein JW, Kalmar JR. Systematic review:bisphosphonate and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61   DOI   PUBMED   ScienceOn